Treating comorbidities in MS is disease modifying: Commentary.
作者信息
Palladino Raffaele
机构信息
Department of Public Health, University 'Federico II' of Naples, Naples, Italy.
Department of Primary Care and Public Health, Imperial College of London, London, UK.
出版信息
Mult Scler. 2025 May;31(6):639-641. doi: 10.1177/13524585251338755. Epub 2025 May 3.
Abstract
摘要
相似文献
1
Treating comorbidities in MS is disease modifying: Commentary.治疗多发性硬化症的合并症具有疾病修饰作用：评论
Mult Scler. 2025 May;31(6):639-641. doi: 10.1177/13524585251338755. Epub 2025 May 3.
2
Treating comorbidities in MS is disease modifying: No.治疗多发性硬化症的合并症具有疾病修饰作用：否。
Mult Scler. 2025 May;31(6):637-639. doi: 10.1177/13524585251338739. Epub 2025 May 3.
3
The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans.在私营部门健康计划中使用疾病修正新药治疗多发性硬化症。
Clin Ther. 2004 Aug;26(8):1341-54. doi: 10.1016/s0149-2918(04)80225-x.
4
Prevalence of comorbidities in patients with multiple sclerosis using administrative data from 2007 to 2016 in Iran.2007 年至 2016 年伊朗基于行政数据的多发性硬化症患者合并症患病率。
Mult Scler Relat Disord. 2023 Jun;74:104693. doi: 10.1016/j.msard.2023.104693. Epub 2023 Mar 31.
5
Comorbidity in Multiple Sclerosis.多发性硬化症中的合并症
Front Neurol. 2020 Aug 21;11:851. doi: 10.3389/fneur.2020.00851. eCollection 2020.
6
The Prevalence of Comorbidities Associated with Multiple Sclerosis in Saudi Arabia.沙特阿拉伯多发性硬化症相关合并症的患病率
Ann Afr Med. 2024 Oct 1;23(4):600-605. doi: 10.4103/aam.aam_49_24. Epub 2024 Aug 13.
7
Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis.与多发性硬化症中起始高效疾病修正治疗药物而非中效疾病修正治疗药物相关的因素。
Mult Scler Relat Disord. 2024 Nov;91:105896. doi: 10.1016/j.msard.2024.105896. Epub 2024 Sep 19.
8
Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.研究合并症对多发性硬化症疾病修正治疗使用情况的影响。
Neurology. 2016 Apr 5;86(14):1287-1295. doi: 10.1212/WNL.0000000000002543. Epub 2016 Mar 4.
9
Vascular comorbidities in the onset and progression of multiple sclerosis.多发性硬化症发病和进展中的血管合并症。
J Neurol Sci. 2014 Dec 15;347(1-2):23-33. doi: 10.1016/j.jns.2014.10.020. Epub 2014 Oct 16.
10
The prevalence of comorbidities in patients with multiple sclerosis: population-based registry data.多发性硬化症患者共病的患病率：基于人群的登记数据。
Neurol Sci. 2021 May;42(5):1887-1893. doi: 10.1007/s10072-020-04727-5. Epub 2020 Sep 22.
本文引用的文献
1
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK.评估辛伐他汀在延缓继发进展型多发性硬化症残疾进展中的有效性（MS-STAT2）：英国一项多中心、随机对照、双盲、3期临床试验方案
BMJ Open. 2024 Sep 16;14(9):e086414. doi: 10.1136/bmjopen-2024-086414.
2
Etiology, effects and management of comorbidities in multiple sclerosis: recent advances.多发性硬化症共病的病因、影响和管理：最新进展。
Front Immunol. 2023 May 30;14:1197195. doi: 10.3389/fimmu.2023.1197195. eCollection 2023.
3
Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders.自身免疫病的治疗：疾病修饰疗法对多发性硬化症和合并自身免疫性疾病的影响。
Autoimmun Rev. 2023 May;22(5):103312. doi: 10.1016/j.autrev.2023.103312. Epub 2023 Mar 15.
4
Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.与多发性硬化症患者使用鞘氨醇-1-磷酸受体调节剂相关的心血管不良事件风险：来自 15 项随机对照试验的汇总分析见解。
Front Immunol. 2021 Dec 7;12:795574. doi: 10.3389/fimmu.2021.795574. eCollection 2021.
5
Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in England.评估英格兰多发性硬化症患者发生大血管事件和死亡的风险。
JAMA Neurol. 2020 Jul 1;77(7):820-828. doi: 10.1001/jamaneurol.2020.0664.
6
Management of diabetes and hypertension in people with multiple sclerosis.多发性硬化症患者的糖尿病和高血压管理。
Mult Scler Relat Disord. 2020 May;40:101987. doi: 10.1016/j.msard.2020.101987. Epub 2020 Feb 8.
7
Vascular aspects of multiple sclerosis: emphasis on perfusion and cardiovascular comorbidities.多发性硬化的血管方面：重点关注灌注和心血管合并症。
Expert Rev Neurother. 2019 May;19(5):445-458. doi: 10.1080/14737175.2019.1610394. Epub 2019 May 10.
8
Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course.高血压、糖尿病、高脂血症和阻塞性肺疾病对多发性硬化病程的影响。
Mult Scler. 2017 Feb;23(2):277-285. doi: 10.1177/1352458516650512. Epub 2016 Jul 11.
9
Differing trends in the incidence of vascular comorbidity in MS and the general population.多发性硬化症（MS）与普通人群中血管合并症发病率的不同趋势。
Neurol Clin Pract. 2016 Apr;6(2):120-128. doi: 10.1212/CPJ.0000000000000230.
10
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview.对多发性硬化症合并症发病率和患病率的系统评价：概述。
Mult Scler. 2015 Mar;21(3):263-81. doi: 10.1177/1352458514564491. Epub 2015 Jan 26.
Zotero 插件